Song Yuzhe, Huang Lijuan, Hu Hao, Jiang Cheng, Zhao Feng, Chang Peng
The Second School of Clinical Medicine, Lanzhou University.
Department of Cardiology.
Acta Cardiol Sin. 2025 Jul;41(4):557-564. doi: 10.6515/ACS.202507_41(4).20250310A.
This study aims to evaluate the feasibility, efficacy, procedural complications, and long-term outcomes of left ventricular (LV) endocardial pacing lead implantation at the latest activation site of the LV. This procedure is guided by three-dimensional (3D) mapping and performed via transseptal puncture, and targets heart failure (HF) patients who either do not respond to conventional cardiac resynchronization therapy (CRT) or face challenges in lead implantation.
A retrospective analysis of clinical data was performed on 11 patients with dilated cardiomyopathy who were treated with LV endocardial pacing. Compared to conventional CRT, this procedure required longer operation and fluoroscopy times and higher radiation dose. Clinical improvements, as evidenced by at least one New York Heart Association class improvement, were achieved in 63.6% of the patients, with an average decrease in Minnesota Living with Heart Failure Questionnaire score of 33.8 ± 2.2 points (p < 0.05). However, complications and adverse events were noted in 3 patients (27.3%) one month postoperatively, including pocket hematomas in 3 patients (27.3%), a pocket infection in 1 patient (9.1%), and a thromboembolic event in 1 patient (9.1%). In addition, 3 patients (27.3%) had worsening HF after implantation. The estimated mortality rates at 1, 3, and 5 years post-implantation were 9.1%, 18.2%, and 27.3%, respectively.
Implanting the LV endocardial pacing lead at the latest activation site under 3D mapping guidance via transseptal puncture offers a viable alternative for patients eligible for CRT who face challenges with LV epicardial lead implantation due to anatomical issues or CRT non-response. However, this procedure is associated with a relatively high incidence of complications, requires careful patient selection, and may necessitate lifelong anticoagulation after implantation.
本研究旨在评估在左心室(LV)最晚激动部位植入左心室内膜起搏导线的可行性、疗效、手术并发症及长期预后。该手术由三维(3D)标测引导,经房间隔穿刺进行,目标人群为对传统心脏再同步治疗(CRT)无反应或在导线植入方面面临挑战的心力衰竭(HF)患者。
对11例接受左心室内膜起搏治疗的扩张型心肌病患者的临床资料进行回顾性分析。与传统CRT相比,该手术需要更长的手术时间和透视时间,且辐射剂量更高。63.6%的患者实现了临床改善,表现为纽约心脏协会心功能分级至少改善一级,明尼苏达心力衰竭生活质量问卷评分平均降低33.8±2.2分(p<0.05)。然而,术后1个月有3例患者(27.3%)出现并发症和不良事件,包括3例患者(27.3%)出现囊袋血肿,1例患者(9.1%)出现囊袋感染以及1例患者(9.1%)出现血栓栓塞事件。此外,3例患者(27.3%)在植入后心力衰竭加重。植入后1年、3年和5年的估计死亡率分别为9.1%、18.2%和27.3%。
在3D标测引导下经房间隔穿刺在左心室最晚激动部位植入左心室内膜起搏导线,为因解剖问题或CRT无反应而在左心室心外膜导线植入方面面临挑战的符合CRT条件的患者提供了一种可行的替代方案。然而,该手术并发症发生率相对较高,需要仔细选择患者,且植入后可能需要终身抗凝。